Key result
Influenza vaccination linked to ~44% lower primary liver cancer risk in patients with hypertension.
Why the study?
Previous studies indicated influenza vaccination may reduce risks of certain cancers, but its protective effect against primary liver cancer in individuals with hypertension remained unclear.
Does influenza vaccination reduce the risk of primary liver cancer in patients over 55 years of age with hypertension?
Cohort (n=37,022)
Does influenza vaccination reduce the risk of primary liver cancer in patients over 55 years of age with hypertension?
In patients over 55 years of age with hypertension, influenza vaccination is associated with a significant, dose-dependent reduction in the risk of developing primary liver cancer.
May not yet change vaccination practice in hypertension; leaves open a potential protective association needing prospective confirmation.
BACKGROUND: previous studies have indicated that influenza vaccination may be associated with reduced risks of certain types of cancer. However, the protective effect of influenza vaccination against primary liver cancer in individuals with hypertension remains unclear. METHODS: In this cohort study, 37,022 patients over 55 years of age who received a diagnosis of hypertension at any time between January 1, 2001, and December 31, 2012, were enrolled from the National Health Insurance Research Database. The patients were divided into a vaccinated and an unvaccinated group. Categorical and continuous variables were analyzed using the chi-square test and t test, respectively, and the correlation between influenza vaccination and liver cancer in patients with hypertension was analyzed using time-varying COX model. Propensity score method was performed to reduce selection bias. RESULTS: Compared with the unvaccinated group, the vaccinated group had a significantly lower incidence of liver cancer (hazard ratio = 0.56, 95% confidence interval = 0.46-0.64; p < .001). In addition, a protective effect was observed regardless of sex, age, or comorbidities. Besides, the association was dose-dependent which could be noted when patients were stratified based on the total number of vaccinations. The adjusted HRs for patients receiving 1, 2 to 3, and ≥ 4 vaccinations during the follow-up period were 0.60 (0.51-0.78), 0.48 (0.38-0.65), and 0.39(0.30-0.51), respectively. CONCLUSIONS: In summary, influenza vaccination is linked to a decreased risk of liver cancer in individuals with hypertension. However, unmeasurable confounders may have been present in the analysis.
No takes yet. Share an insight, caveat, or question.
Chiu et al. (2025) conducted a cohort in Hypertension (n=37,022). Influenza vaccination vs. Unvaccinated was evaluated on Occurrence of primary liver cancer (HR 0.56, 95% CI 0.46-0.64, p=<0.001). Influenza vaccination was associated with a significantly lower incidence of primary liver cancer compared to no vaccination in patients with hypertension (HR 0.56).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: